Overview

A Study of EPEG in Beta Thalassemia Patients

Status:
Completed

Trial end date:
2017-09-27

Target enrollment:

Participant gender:

Summary

An open-label study in which 6 patients will receive once-weekly subcutaneous injections of EPEG for 4 weeks. Final visit will occur 60 days after study entry

Phase:

Phase 1

Details

Lead Sponsor:

Prolong Pharmaceuticals